The revenue of the dermatological drugs market in 2018 is estimated at $31bn and is expected to grow at a CAGR of 3.7% in the first half of the forecast period. Psoriasis drugs segment accounted for the largest share of the market in 2018, this segment accounted for 38% of the global dermatological drugs market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 355-page report you will receive 133 tables and 154 figures– all unavailable elsewhere.
The 355-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Dermatological drugs market forecasts from 2020-2030
• This report also breaks down the revenue forecast for the main submarkets: • Psoriasis • Skin Infections • Acne • Dermatitis
• Analysis of the Psoriasis drugs market. Revenue forecasts to 2030 are provided for the following drugs: • Humira • Stelara • Enbrel • Remicade • Taltz • Otezla • Cosentyx
• Analysis of the Skin Infections drugs market. Revenue forecasts to 2030 are provided for the following drugs: • Cubicin • Zyvox • Valtrex • Canesten • Lamisil • Bactroban
• Analysis of the Acne drugs market. Revenue forecasts to 2030 are provided for the following drugs: • Solodyn • Epiduo • Claravis • Aczone • Differin • Abscorical/Epirus • Ziana • Doryx
• Analysis of the Dermatitis drugs market. Revenue forecasts to 2030 are provided for the following drugs: • Bepanthen/Bepanthol • Protopic • Dermovate • Elocon
• This report provides individual revenue forecasts to 2030 for these regional and national markets: • North America: US & Canada • Europe: Germany, France, UK, Italy, Spain, Rest of Europe • Asia-Pacific: China, Japan, India, Rest of Asia-Pacific • Latin America: Brazil, Mexico, Rest of Latin America • Middle East & Africa (MEA): Saudi Arabia, South Africa, Rest of MEA
Each regional market is further segmented by indication: psoriasis, skin infection, acne, dermatitis and others.
• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.
• Our study includes SWOT analysis and Porter’s Five Force analysis of the dermatological drugs market.
• Our study discusses the selected leading companies that are the major players in the dermatological drugs market: • AbbVie • Allergan • Amgen • Bausch Health • Bayer AG • Bristol-Myers Squibb • Celgene Corporation • Eli Lilly • Galderma (Nestle Skin Health S.A.) • GlaxoSmithKline (GSK) • Johnson & Johnson • LEO Pharma • Merck & Co, Inc. • Novartis • Pfizer
• Key questions answered by this report: • How is the dermatological drugs market evolving? • What is driving and restraining the dermatological drugs market? • What are the market shares of each segment of the overall dermatological drugs market in 2019? • How will each dermatological drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? • How will the market shares for each dermatological drugs submarket develop from 2020 to 2030? • Which individual therapies will prevail and how will these shifts be responded to? • What will be the main driver for the overall market from 2020 to 2030? • How will political and regulatory factors influence the regional markets and submarkets? • Will leading national dermatological drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? • How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? • Who are the leading players and what are their prospects over the forecast period? • How will the industry evolve during the period between 2019 and 2030? • Visiongain understands that the dermatological drugs market will register strong growth. This report examines in detail the market by region, by submarket, and as a whole, and provides the reader with a thorough overview of the market to identify key growth areas and business opportunities to exploit. This is where Visiongain adds value.
Visiongain’s study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview 1.1 Global Dermatological Drugs Market Overview 1.2 Overview of Findings 1.3 Structure of the Report 1.4 Global Dermatological Drugs Market Segmentation 1.5 Why You Should Read This Report 1.6 How This Report Delivers 1.7 Key Questions Answered by This Analytical Report 1.8. Who is This Report For? 1.9 Methodology 1.10 Associated Visiongain Reports 1.11 About Visiongain
2. Introduction to Dermatological Drugs 2.1 The Pharmaceutical Industry: A Brief Introduction 2.2 An Introduction to Dermatology 2.2.1 The Structure of Skin, Hair, and Nails 2.2.2 Hair and Nails 2.2.3 Sweat and Sebaceous Glands 2.2.4 Functions of the Skin 2.3 Common Skin Diseases 2.3.1 Acne: The Most Common Skin Disease 2.3.1.1 Acne: Epidemiology 2.3.1.2 Acne: Causes and Pathogenesis 2.3.1.3 Acne: Treatment 2.3.2 Dermatitis: Inflammation of the Skin 2.3.2.1 Atopic Dermatitis 2.3.2.2 Contact Dermatitis 2.3.2.3 Seborrhoeic Dermatitis 2.3.2.4 Nummular Dermatitis 2.3.2.5 Perioral Dermatitis 2.3.3 Psoriasis: A Complex Multi-Factorial Disease 2.3.4 Rosacea: Vascular Instability 2.3.5 Alopecia: Excessive Shedding of Hair 2.4 Skin Infections: A Serious Healthcare Threat 2.4.1 Bacterial Skin Infections 2.4.2 Fungal Skin Infections 2.4.3 Viral Skin Infections 2.5 Common Skin Treatments 2.5.1 Creams and Semisolid Emulsions 2.5.2 Ointments 2.5.3 Lotions 2.5.4 Solutions 2.5.5 Occlusive Therapy 2.5.6 Cleansing Agents 2.5.7 Powders and Hydrophilic Polymer 2.5.8 Anti-Infective Agents 2.5.9 Anti-Inflammatory Agents 2.6 Phases of Clinical Trials 2.7 Dermatological Drugs: Market Definition in this Report 3. Global Dermatological Drugs Market by Indication 2020-2030 3.1 The Global Dermatological Drugs Market: Market Overview 3.2 Categorisation of the Global Dermatological Drugs Market 3.3 The Global Dermatological Drugs Market in 2019 3.4 The Global Dermatological Drugs Market: Market Forecast 2020-2030 3.5 Changing Market Shares by Segment 2020-2030
4. The Psoriasis Drugs Market: Market Analysis and Forecast 2020-2030 4.1 Psoriasis Treatments: The Dominance of Biologics 4.1.1 Leading Products in the Psoriasis Drugs Market, 2019 4.2 Psoriasis: Market Trends and Developments, 2019 4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview 4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing 4.2.3 Biosimilars and Interchangeables 4.2.3.1 Extrapolation of indications 4.2.3.2 Biosimilar interchangeability in the EU 4.2.3.3 Biosimilar guidance in the US 4.2.3.4 The Disadvantages of Biologics in Psoriasis Treatment 4.3 Psoriasis Drugs: Market Forecast 2020-2030 4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2020-2030 4.4 Leading Drugs Used in the Treatment of Psoriasis 4.4.1 Humira (adalimumab) - AbbVie 4.4.1.1 Humira: Historical Sales Analysis, 2010-2017 4.4.1.2 Humira: Sales Forecast 2020-2030 4.4.1.3 Future Prospects for Biosimilar Versions of Humira 4.4.2 Stelara (ustekinumab) – Johnson & Johnson 4.4.2.1 Stelara New Market Leader, Ahead of Humira 4.4.2.2 Stelara: Historical Sales Analysis, 2010-2017 4.4.2.3 Stelara: Sales Forecast 2020-2030 4.4.2.4 Intensifying Competition for Stelara 4.4.3 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda 4.4.3.1 Enbrel: Co-Promotions and Marketing Rights 4.4.3.2 Enbrel: Historical Sales Analysis, 2009-2017 4.4.3.3 Enbrel: Patent Expiries and Potential Competition, 2020-2030 4.4.3.4 Patent Litigation with Sandoz Over Enbrel 4.4.3.5 Enbrel: Sales Forecast 2020-2030 4.4.3.6 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years 4.4.3.7 Competition from Other Drugs 4.4.3.8 Biosimilar Competition for Enbrel 4.4.4 Remicade (infliximab) – Johnson & Johnson 4.4.4.1 Remicade: Historical Sales Analysis, 2009-2017 4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2020-2030 4.4.4.3 Remicade: Sales Forecast 2020-2030 4.4.5 Taltz (ixekizumab) – Eli Lilly 4.4.5.1 Taltz: Sales Forecast 2020-2030 4.4.6 Otezla (apremilast) – Celgene 4.4.6.1 Otezla: Sales Forecast 2020-2030 4.4.7 Cosentyx (secukinumab) - Novartis 4.4.7.1 Cosentyx: Sales Forecast 2020-2030 4.4.8 Other Psoriasis Drugs 4.4.8.1 Cimzia (certolizumab) - UCB 4.4.8.2 Sorilux (calcipotriene foam) - GSK 4.4.8.3 Siliq (brodalumab) - AstraZeneca/ LEO Pharma 4.4.8.4 Other Psoriasis Drugs: Sales Forecast 2020-2030 4.5 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis and Forecast 2020-2030 5.1 Skin Infection Drugs: Abundant Growth Opportunities 5.1.1 Leading Products in the Skin Infection Drugs Market, 2019 5.2 Skin Infection Drugs: Market Forecast 2020-2030 5.2.1 Skin Infection: Changing Market Shares by Leading Drugs 2020-2030 5.3 Leading Drugs Used in the Treatment of Skin Infections 5.3.1 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co 5.3.2 Acquisition by Merck & Co 5.3.3 Generic Competition for Cubicin 5.3.4 Cubicin: Sales Forecast 2020-2030 5.3.5 Lifecycle Management Strategies for Cubicin 5.4 Zyvox (linezolid) - Pfizer 5.4.1 Zyvox: Historical Sales Analysis, 2010-2017 5.4.2 Zyvox: Sales Forecast 2020-2030 5.4.3 The Threats to Zyvox Sales from Competing New Drugs 5.5 Canesten (clotrimazole) - Bayer 5.5.1 Canesten: Historical Sales Analysis, 2011-2017 5.5.2 Canesten: Sales Forecast 2020-2030 5.6 Valtrex (valaciclovir) - GSK 5.6.1 Valtrex: Historical Sales Analysis, 2010-2017 5.6.2 Valtrex: Sales Forecast 2020-2030 5.7 Sivexto 5.7.1 Sivexto: Sales Forecast 2020-2030 5.8 Lamisil (terbinafine) - Novartis 5.8.1 Lamisil Patent Expiry 5.8.2 Lamisil Sales Affected by Novartis Manufacturing Problems 5.8.3 Lamisil: Sales Forecast 2020-2030 5.9 Other Skin Infection Drugs 5.9.1 Dalvance (dalbavancin) - Durata Therapeutics 5.9.2 Jublia (efinaconazole) - Valeant 5.9.3 Kerydin (tavaborole) - Anacor 5.9.4 Zovirax (acyclovir) - Valeant/GSK 5.9.4.1 Valeant Acquires Zovirax in US and Canada 5.9.4.2 Mylan‟s Generic Zovirax and Actavis‟ Authorised Generic 5.9.5 Other Skin Infection Drugs: Sales Forecast 2020-2030 5.10 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis and Forecast 2020-2030 6.1 Acne Drugs: A Diversified Market 6.1.1 Leading Products in the Acne Drugs Market, 2019 6.2 Acne Drugs Market: Recent Trends and Developments 6.2.1 The Rise of Combination Therapies in Acne Treatment 6.2.2 Oral Contraceptives in Treating Acne 6.2.3 The Threat of Generic Competition in the Acne Drugs Market 6.3 Acne Drugs: Market Forecast 2020-2030 6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2020-2030 6.4 Leading Drugs in the Acne Drugs Market 6.4.1 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health 6.4.1.1 Epiduo: Sales Forecast 2020-2030 6.4.1.2 Galderma Settlement Agreement over Generic Epiduo 6.4.1.3 Paediatric Approval for Epiduo 6.4.2 Solodyn (minocycline) - Valeant 6.4.2.1 Solodyn: Sales Forecast 2020-2030 6.4.2.2 Antitrust Action over Solodyn Pay-For-Delay Deals 6.4.2.3 Impax and Medicis Collaborating on Advanced Solodyn 6.4.2.4 Medicis and Lupin Settle 6.4.3 Claravis (isotretinoin) - Teva 6.4.3.1 Claravis: Sales Forecast 2020-2030 6.4.4 Aczone (dapsone) - Allergan 6.4.4.1 Aczone: Sales Forecast 2020-2030 6.4.5 Retin-A Micro – Bausch Health 6.4.5.1 Retin-A Micro: Sales Forecast 2020-2030 6.4.6 Absorica/Epuris (CIP-isotretinoin) – Cipher/Sun Pharma 6.4.6.1 Absorica/Epuris: Sales Forecast 2020-2030 6.4.7 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International 6.4.7.1 Valeant‟s Patent Settlement with Actavis over Ziana 6.4.7.2 Ziana: Sales Forecast 2020-2030 6.4.8 Acanya (clindamycin/benzoyl peroxide) – Dow /Valeant 6.4.8.1. Actavis Claims First-to-File Exclusivity for its Acanya 6.4.8.2 Legal Battles Involving Dow/Valeant, Perrigo, and 6.4.8.3 Acanya: Sales Forecast 2020-2030 6.4.9 Other Acne Drugs 6.4.9.1 Doryx (doxycycline) – Actavis/Mayne Pharma 6.4.9.1.1 Lifecycle Management Strategies for Doryx 6.4.9.1.2 Divestment Agreement with Mayne Pharma 6.4.9.1.3 Generic Competition for Doryx 6.4.9.2 Amnesteem (isotretinoin) - Mylan 6.4.9.2.1 Amnesteem: Financial Analysis 6.4.9.3 Diane (cyproterone/ethinyl estradiol) - Bayer 6.4.9.4 Duac (clindamycin/benzoyl peroxide) – 6.4.9.5 Veltin (tretinoin/clindamycin) - GSK 6.4.9.6 Other Acne Drugs: Sales Forecast 2020-2030 6.5 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis and Forecast 2020-2030 7.1 Dermatitis Drugs: High Generic Penetration 7.1.1 Leading Products in the Dermatitis Drugs Market, 2019 7.2 Dermatitis Drugs: Market Forecast 2020-2030 7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2020-2030 7.3 Leading Drugs in the Dermatitis Drugs Market 7.3.1 Bepanthen (dexpanthenol)/ Bepanthol - Bayer 7.3.1.1 Bepanthen: Sales Forecast 2020-2030 7.3.2 Elocon (mometasone) - Merck & Co 7.3.2.1 Elocon: Sales Forecast 2020-2030 7.3.3 Protopic (tacrolimus) – LEO Pharma 7.3.3.1 Protopic Benefits from Expanded Indication 7.3.3.2 Generic Competition for Protopic 7.3.3.3 Protopic: Sales Forecast 2020-2030 7.3.4 Dermovate -GSK 7.3.4.1 Dermovate: Sales Forecast 2020-2030 7.3.5 Other Dermatitis Drugs: Sales Forecast 2020-2030 7.4 Dermatitis Drugs: Market Outlook
8. Leading National Markets 2020-2030 8.1. Geographical Breakdown of the World Dermatological Drugs Market 8.2 World Dermatological Drugs Market: Regional Forecast 2020-2030 8.2.1 How Will Regional Market Shares Change to 2030?
9. North America Dermatological Drugs Market 2020-2030 9.1. U.S. Dermatological Drugs Market: Trends and Developments 9.1.1. Obamacare Repeal 9.1.2. Legislative Environment Stimulating Biosimilars 9.1.3 Biosimilar Interchangeability guidance in the US 9.1.4 US Dermatological Drugs Market: Market Forecast 2020-2030 9.2. Canada Dermatological Drugs Market: Trends and Developments
10. Europe Dermatological Drugs Market 2020-2030 10.1 Europe Markets: Changing Market Shares by Country, 2020-2030 10.2 Germany 10.2.1 Germany Dermatological Drugs Market: Market Forecast 2020-2030 10.3. France Dermatological Drugs Market Forecast 2020-2030 10.4. U.K. 10.4.1 The Impact of Brexit On the Dermatological Drugs 10.4.2 Pricing and Reimbursement 10.4.3 New Regulatory Body and Clinical Trials 10.4.4 Patent Protection 10.4.5 Research and Funding 10.4.6. U.K. Dermatological Drugs Market Forecast 2020-2030 10.5 Italy 10.5.1 Italy Dermatological Drugs Market Forecast 2020-2030 10.6. Spain Dermatological Drugs Market Forecast 2020-2030 10.7. Rest of Europe Dermatological Drugs Market Forecast 2020-2030 10.7.1 Russia 10.7.1.1 Pharma2020 Strategy - Healthcare and Industry Reform 11. Asia-Pacific Dermatological Drugs Market 2020-2030 11.1 China 11.1.1 Expansion of Healthcare Coverage and Reimbursement in China 11.1.2 Improving Public Perception of Dermatology in China 11.1.3 Price Controls and the Anhui Model 11.1.4 Chinese Dermatological Drugs Market Forecast 2020-2030 11.2. Japan Dermatological Drugs Market: Trends and Developments 11.2.1 The Cost of Treatment in Japan 11.2.2 Japanese Pharmaceutical Industry Regulatory Reform 11.2.3 Japanese Dermatological Drugs Market Forecast 2020-2030 11.3. India 11.3.1 The Effects of the Drug Prices Control Order of 2013 11.3.2 India‟s Expansion of Healthcare Provision 11.3.3 Revised Biosimilar Guidelines 11.3.4 Indian Dermatological Drugs Market Forecast 2020-2030 11.4. Rest of Asia-Pacific Dermatological Drugs Market: Trends and Developments
12. Latin America Dermatological Drugs Market 2020-2030 12.1 Brazil 12.1.1 The Growth in Brazil‟s Healthcare Landscape 12.1.2 Clearer Access to Medicines in Brazil 12.1.3 Brazil Dermatological Drugs Market Forecast 2020-2030 12.2. Mexico Dermatological Drugs Market: Trends and 12.3. Rest of Latin America Dermatological Drugs Market: Trends and Developments
13. Middle East & Africa Dermatological Drugs Market 2020-2030 13.1. Saudi Arabia Dermatological Drugs Market Forecast 2020-2030 13.2. South Africa Dermatological Drugs Market Forecast 2020-2030 13.3. Rest of Middle East & Africa Dermatological Drugs Market Forecast 2020-2030 14. Leading Companies in the Dermatological Drugs Market 14.1. Galderma (Nestle Skin Health S.A.) 14.1.1 Galderma: Dermatological Drugs Product Portfolio 14.1.2 Financial Overview 14.1.3. Recent Transactions Summary 14.2. Johnson & Johnson 14.2.1. Johnson & Johnson: Dermatological Drugs Product Portfolio 14.2.2 Financial Overview 14.2.2.1 Pipeline, 2019 14.2.3. Recent Transactions Summary 14.3. GlaxoSmithKline plc 14.3.1 GlaxoSmithKline plc: Dermatological Drugs Portfolio 14.3.2 GlaxoSmithKline plc: Financial Overview 14.3.3 GlaxoSmithKline plc: Recent Transactions Summary 14.4. Pfizer, Inc. 14.4.1 Pfizer, Inc.: Dermatological Drugs Portfolio 14.4.2 Pfizer, Inc.: Financial Overview 14.4.3 Pfizer, Inc.: Recent Developments 14.4.4 Pfizer: Dermatological Drugs Development Pipeline, 2019 14.5.LEO Pharma A/S 14.5.1 LEO Pharma A/S.: Dermatological Drugs Product Portfolio 14.5.2 Financial Overview 14.5.3 Recent Transactions Summary 14.6. AbbVie Inc. 14.6.1 AbbVie Inc.: Dermatological Drugs Product Portfolio 14.6.2 Financial Overview 14.6.3 Recent Transactions Summary 14.7. Novartis AG 14.7.1 Novartis: Dermatological Drugs Portfolio 14.7.2 Novartis: Financial Overview 14.7.3 Novartis: Recent Developments 14.8. Amgen, Inc. 14.8.1 Amgen, Inc.: Dermatological drugs Portfolio 14.8.2 Financial Overview 14.8.3. Recent Transactions Summary 14.9. Merck & Co., Inc. 14.9.1 Merck & Co., Inc.: Dermatological Drugs Portfolio 14.9.2 Merck & Co., Inc.: Financial Overview 14.9.3 Merck & Co., Inc.: Recent Transactions Summary 14.10. Bayer AG 14.10.1 Bayer AG: Dermatological Drugs Portfolio 14.10.2 Bayer AG: Financial Overview 14.10.3 Bayer AG: Recent Transactions Summary 14.11. Celgene Corporation 14.11.1 Celgene Corporation: Dermatological Drugs Product Portfolio 14.11.2 Celgene Corporation: Financial Overview 14.11.3 Celgene Corporation: Recent Transactions Summary 14.12. Bausch Health Companies Inc. 14.12.1 Bausch Health Companies Inc.: Dermatological Drugs Product Portfolio 14.12.2 Bausch Health Companies Inc.: Dermatological Drugs Product Pipeline 14.12.3 Bausch Health Companies Inc.: Financial Overview 14.12.4 Bausch Health Companies Inc.: Recent Developments 14.13. Bristol-Myers Squibb Company 14.13.1 Bristol-Myers Squibb Company: Dermatological Drugs Product Portfolio 14.13.2 Bristol-Myers Squibb Company: Dermatological Drugs Product Pipeline 14.13.3 Bristol-Myers Squibb Company: Financial Overview 14.13.4 Bristol-Myers Squibb Company: Recent Transactions Summary 14.14. Allergan plc 14.14.1 Allergan plc: Dermatological Drugs Product Portfolio 14.14.2 Allergan plc: Financial Overview 14.14.3 Allergan plc: Recent Transactions Summary 14.15. Eli Lilly and Company 14.15.1 Eli Lilly and Company: Dermatological Drugs Product Portfolio 14.15.2 Eli Lilly and Company: Financial Overview 14.15.3 Eli Lilly and Company: Recent Transactions Summary
15. Dermatological Drugs: Research and Development Pipeline, 2020-2030 15.1 Innovative Products Currently in Development Will Drive Growth 15.1.1 New Technology in R&D Pipeline Activities 15.1.1.1 Reformulation 15.1.1.2 Combination Treatments 15.1.1.3 New Mechanisms and Drug Delivery Technologies 15.1.1.4 Potential Market Entrants 15.2 Psoriasis Drugs Development Pipeline, 2019 15.2.1 Psoriasis Drugs in Phase 3 Development or 15.2.1.2 CF101 (Piclidenoson) - Can-Fite BioPharma 15.2.2 Psoriasis Drugs in Phase 2 Development 15.2.2.1 LY3009104 (baricitinib) - Incyte/ Eli Lilly 15.2.2.2 PH-10 (Rose Bengal) – Provectus 15.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical 15.3 Skin Infection Drugs Development Pipeline, 2019 15.3.1 Drugs in Phase 3 Development for Skin Infections 15.3.1.1 Baxdela (delafloxacin) - Melinta Pharmaceuticals 15.3.1.2 NB-001 - NanoBio Corporation 15.3.1.3 Luliconazole - Topica Pharmaceuticals 15.3.2 Drugs in Phase 2 Development for Skin Infections 15.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections 15.4 Acne Drugs Development Pipeline, 2019 15.4.1 Drugs in Phase 3 Development for Acne 15.4.1.2 Visonac (photodynamic therapy) - Photocure 15.4.2 Drugs in Phase 2 Development for Acne 15.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne 15.4.4 A Possible Vaccine for Acne 15.5 Dermatitis Drugs Development Pipeline, 2019 15.5.1 Drugs in Phase 3 Development for Dermatitis 15.5.1.1 Toctino (alitretinoin) - GSK 15.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher 15.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre 15.5.1.4 REGN668/SAR231893 (dupilumab) - 15.5.2 Drugs in Phase 2 Development for Dermatitis 15.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis 15.6 Other Dermatological Drugs Development Pipeline, 2019 15.6.1 Other Dermatological Drugs: Filed or Recently 15.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall 15.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera 15.6.1.3 Mirvaso (brimonidine) - Galderma 15.6.1.4 Picato (ingenol mebutate) - LEO Pharma 15.6.1.5 Xolair (omalizumab) - Novartis/ Roche 15.6.2 Other Dermatological Drugs: Phase 3 Pipeline 15.6.2.1 CD5024 (ivermectin) - Galderma 15.6.2.2 SR-T100 gel (Solanum incanum extract) - G&E 15.6.3 Other Dermatological Drugs: Phase 2 Pipeline
16. Qualitative Analysis of the Dermatological Drugs Market, 2020-2030 16.1 Market Factors Influencing Dermatological Drugs 16.2 SWOT Analysis of the Global Dermatological Drugs Market, 2020-2030 16.2.1 Strengths 16.2.1.1 The High Unmet Clinical Need in Dermatology 16.2.1.2 A Healthy Pipeline of Development-Stage Products 16.2.1.3 Strong Industry-Physician Relationships 16.2.2 Weaknesses 16.2.2.1 Limited Efficacy and Adverse Effects May Impact 16.2.2.2 Patient Adherence – A Major Challenge to 16.2.2.3 Impending Patent Expiries and the Challenges 16.2.3 Opportunities 16.2.3.1 The High-Growth Sectors in Dermatology 16.2.3.2 Personalised Dermatology: Technological Advances in Genomics 16.2.3.3 Advances in Topical Drug Delivery Methods Offers 16.2.3.4 Consolidation within Dermatology – Opportunity for Synergistic Growth? 16.2.4 Threats 16.2.4.1 Uncertainty Surrounding Reimbursement and 16.2.4.2 The Rising Cost of Research and Development 16.2.4.3 Downward Pressures on Drug Prices 16.3 Porter‟s Five Force Analysis of the Global Dermatological Drugs Market, 2020-2030 16.3.1 Threat of New Entrants 16.3.2 Threat of Substitutes 16.3.3 Rivalry among Competitors 16.3.4 Power of Buyers 16.3.5 Power of Suppliers
17. Conclusions 17.1 Overview of Current Market Conditions and Market Forecast, 2020-2030 17.2 Leading Sectors in Dermatological Drugs in 2019 17.3 Leading Regions in the Dermatological Drugs Market in 2019 17.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2020-2030 17.5 What Does the Future Hold for Dermatological Drugs? Appendices Associated Visiongain Reports Global OTC Pharmaceutical Market Forecast 2020-2030 Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
Myeloproliferative Disorders Drugs– our new study reveals trends, R&D progress, and predicted revenues Where is the Myeloproliferative Disorders Drugs market...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
